Periodic ‘adequacy testing’ of urine and spent dialysate is an important activity in assessing efficacy of peritoneal dialysis and detecting complication of therapy, such as membrane fibrosis and peritonitis.Rametrix® UMF™ was able to identify the type of specimen (as PD patient urine or spent dialysate) with better than 98% accuracy, sensitivity, and specificity. UMF was able to identify “unknown” urine specimens either from PD patients or healthy human volunteers with better than 96% accuracy (with better than 97% sensitivity and 94% specificity). This demonstrates that an entire UMF of a urine or spent dialysate specimen can be used to determine its identity or the presence of ESRD in the patient and could be used to evaluate the contribution of residual renal mass to dialysis efficacy, as well as detecting complications (peritoneal fibrosis) associated with treatment. (Senger, R, Sullivan, M, et. al)